Compare Panacea Biotech with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x 12.2 11.9 102.6% View Chart
P/BV x 2.9 1.7 172.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
GLENMARK PHARMA
Mar-19
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs364712 51.2%   
Low Rs129484 26.7%   
Sales per share (Unadj.) Rs96.8349.6 27.7%  
Earnings per share (Unadj.) Rs-12.432.8 -37.9%  
Cash flow per share (Unadj.) Rs-2.944.3 -6.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs50.4198.6 25.4%  
Shares outstanding (eoy) m61.25282.17 21.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.51.7 149.0%   
Avg P/E ratio x-19.918.2 -109.0%  
P/CF ratio (eoy) x-86.413.5 -641.2%  
Price / Book Value ratio x4.93.0 162.6%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m15,101168,625 9.0%   
No. of employees `0002.512.0 20.5%   
Total wages/salary Rs m1,51620,561 7.4%   
Avg. sales/employee Rs Th2,401.98,196.0 29.3%   
Avg. wages/employee Rs Th614.21,708.1 36.0%   
Avg. net profit/employee Rs Th-307.9768.5 -40.1%   
INCOME DATA
Net Sales Rs m5,92898,655 6.0%  
Other income Rs m822,081 4.0%   
Total revenues Rs m6,010100,736 6.0%   
Gross profit Rs m84515,858 5.3%  
Depreciation Rs m5853,259 18.0%   
Interest Rs m1,0063,346 30.1%   
Profit before tax Rs m-66411,335 -5.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m993,756 2.6%   
Profit after tax Rs m-7609,250 -8.2%  
Gross profit margin %14.316.1 88.7%  
Effective tax rate %-14.933.1 -44.8%   
Net profit margin %-12.89.4 -136.7%  
BALANCE SHEET DATA
Current assets Rs m5,60366,968 8.4%   
Current liabilities Rs m6,91040,211 17.2%   
Net working cap to sales %-22.027.1 -81.3%  
Current ratio x0.81.7 48.7%  
Inventory Days Days20683 247.0%  
Debtors Days Days8481 103.1%  
Net fixed assets Rs m9,94133,322 29.8%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m3,02655,770 5.4%   
Net worth Rs m3,08756,052 5.5%   
Long term debt Rs m5,70735,738 16.0%   
Total assets Rs m16,076132,888 12.1%  
Interest coverage x0.34.4 7.8%   
Debt to equity ratio x1.80.6 290.0%  
Sales to assets ratio x0.40.7 49.7%   
Return on assets %1.59.5 16.1%  
Return on equity %-24.616.5 -149.2%  
Return on capital %3.917.8 22.0%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60062,998 2.5%   
Fx outflow Rs m1,13122,859 4.9%   
Net fx Rs m46940,140 1.2%   
CASH FLOW
From Operations Rs m1,18013,242 8.9%  
From Investments Rs m553-6,990 -7.9%  
From Financial Activity Rs m-1,644-7,387 22.2%  
Net Cashflow Rs m90-2,971 -3.0%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS